Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.44 |
| ▸ | APEX1 | P27695 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12047846 | 0.98 | MEN1 (0.46) | APEX1NPSR1MEN1KMT2ANFKB1 | |
| Hydrochloric Acid SCHEMBL28686190 | 0.96 | MEN1 (0.44) | APEX1NPSR1MEN1KMT2ANFKB1 | |
| SCHEMBL5154412 | 0.96 | MEN1 (0.42) | APEX1NPSR1MEN1KMT2ANFKB1 | |
| Hydrochloric Acid SCHEMBL28916544 | 0.92 | APEX1 (0.40) | APEX1NPSR1MEN1KMT2ANFKB1 | |
| SCHEMBL714615 | 0.90 | MEN1 (0.38) | APEX1NPSR1MEN1KMT2ANFKB1 | |
| Hydrochloric Acid SCHEMBL28596004 | 0.83 | APEX1 (0.32) | APEX1NPSR1 | |
| Hydrochloric Acid SCHEMBL5187545 | 0.82 | MEN1 (0.35) | APEX1NPSR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28292601 | 0.81 | DNM1 (0.59) | APEX1NPSR1MEN1KMT2ANFKB1 | |
| SCHEMBL17291829 | 0.80 | PAOX (0.48) | KMT2AKDM4ERAB9AKDM1ACNR1 | |
| SCHEMBL17291817 | 0.80 | PAOX (0.48) | KMT2AKDM4ERAB9AKDM1ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028952-B2 | Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof | SATIOGEN PHARMACEUTICALS, INC (US) | 2018-07-24 | — | — | US | claimed |
| EP-3266457-B1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SHIRE HUMAN GENETIC THERAPIES (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4424363-B1 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | MIRUM PHARMACEUTICALS INC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12599602-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. | 2026-04-14 | — | — | US | disclosed |
| US-12576079-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. | 2026-03-17 | — | — | US | disclosed |
| US-20250375381-A1 | Compositions and methods for treating bile acid malabsorption | COSMO TECHNOLOGIES LTD. (IE) | 2025-12-11 | — | — | US | disclosed |
| US-20250360127-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250360163-A1 | Therapeutic Composition and Methods | VISCERA LABS, INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250282808-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250281482-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| EP-1307263-A2 | NEW USE OF LIPASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-07 | — | — | EP | disclosed |
| EP-1307264-A2 | NEW PHARMACEUTICAL COMPOSITION | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-07 | — | — | EP | disclosed |
| EP-1293211-A1 | Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications | G.D. Searle LLC. (US) | 2003-03-19 | — | — | EP | disclosed |
| EP-1140190-B1 | COMBINATIONS OF ILEAL BILE ACID TRANSPORT INHIBITORS AND BILE ACID SEQUESTERING AGENTS FOR CARDIOVASCULAR INDICATIONS | SEARLE LLC (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020042395-A1 | Administering lipase inhibitors | CHEPLAPHARM ARZNEIMITTEL GMBH (DE) | 2002-04-11 | — | — | US | disclosed |
| US-20020035089-A1 | Orlistat compositions | CHEPLAPHARM ARZNEIMITTEL GMBH (DE) | 2002-03-21 | — | — | US | disclosed |
| WO-2002009815-A2 | NEW PHARMACEUTICAL COMPOSITION | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
| WO-2002009814-A2 | NEW USE OF LIPASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
| EP-1140185-A1 | COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND BILE ACID SEQUESTERING AGENTS FOR CARDIOVASCULAR INDICATIONS | G.D. Searle LLC. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038723-A1 | COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND BILE ACID SEQUESTERING AGENTS FOR CARDIOVASCULAR INDICATIONS | G.D. SEARLE LLC (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035089-A1 | Orlistat compositions | LIPC, CEL, PNLIP | ACHE 348/4885APEX1 4613/4885NPSR1 3087/4885 |
| US-20250281482-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | ACHE 2816/4885APEX1 2714/4885NPSR1 3168/4885 |
| US-20250360127-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | ACHE 2302/4885APEX1 2278/4885NPSR1 1811/4885 |
| US-20250282808-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SLC10A1, SLC10A2, ABCB11 | ACHE 1632/4885APEX1 2586/4885NPSR1 3787/4885 |
| US-10028952-B2 | Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof | SLC10A1, SLC10A2, NR1H4 | ACHE 3272/4885APEX1 4625/4885NPSR1 1190/4885 |
| US-12599602-B2 | Methods for treating cholestasis | SLC10A1, SLC10A2, SLC10A6 | ACHE 1990/4885APEX1 4606/4885NPSR1 2090/4885 |
| US-20250360163-A1 | Therapeutic Composition and Methods | FABP2, GPR119, TTR | ACHE 1713/4885APEX1 3858/4885NPSR1 1838/4885 |
| US-12576079-B2 | Methods for treating cholestasis | SLC10A1, SLC10A2, SLC10A6 | ACHE 4520/4885APEX1 2370/4885NPSR1 4087/4885 |
| US-20020042395-A1 | Administering lipase inhibitors | LIPA, CEL, LIPC | ACHE 251/4885APEX1 3610/4885NPSR1 3052/4885 |
| US-20250375381-A1 | Compositions and methods for treating bile acid malabsorption | SLC10A2, SLC10A1, NR1H4 | ACHE 2022/4885APEX1 4192/4885NPSR1 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.